Ann: FELIX product development and commercialisation update, page-11

I'm not sure if there is any reason to buy this stock until at least half way through 2020.  The product is all but finished and will soon be undergoing trials by key opinion leaders.  After that we need to wait for certification and then commercialisation.  It doesn't seem like there will be any left-field announcements except possibly of the negative kind, i.e. running out of money (I'm not saying that is likely).  I'm sure that Memphasys is already confident of the outcome of the trials as they would have done extensive testing themselves.  Can anyone think of a reason to jump in now with such a long and seemingly uneventful wait until commercialisation?  There just doesn't seem to be any catalyst for the price to go up until then.